Siglec-7 May Limit Natural Killer Cell–mediated Antitumor responses in Bladder Cancer Patients
Authors:
Open Access
- 18 November 2021
- journal article
- research article
- Published by Elsevier in European Urology Open Science
- Vol. 34, 79-82
Abstract
No abstract availableKeywords
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (32003B_146638, 32003B_175559)
This publication has 16 references indexed in Scilit:
- Siglecs as Immune Cell Checkpoints in DiseaseAnnual Review of Immunology, 2020
- The multifaceted immune regulation of bladder cancerNature Reviews Urology, 2019
- Comprehensive Molecular Characterization of Muscle-Invasive Bladder CancerCell, 2017
- Bladder cancerNature Reviews Disease Primers, 2017
- EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016European Urology, 2017
- Resistance to PD1/PDL1 checkpoint inhibitionCancer Treatment Reviews, 2017
- Definitions, End Points, and Clinical Trial Designs for Non–Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer GroupJournal of Clinical Oncology, 2016
- Molecular cloning and expression of a human hST8Sia VI (α2,8-sialyltransferase) responsible for the synthesis of the diSia motif on O-glycosylproteinsBiochemical Journal, 2005
- Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec‐7‐dependent and ‐independent mechanismsEuropean Journal of Immunology, 2003
- RECEPTORS FOR HLA CLASS-I MOLECULES IN HUMAN NATURAL KILLER CELLSAnnual Review of Immunology, 1996